Skip to main
MYO
MYO logo

Myomo (MYO) Stock Forecast & Price Target

Myomo (MYO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Myomo Inc. has demonstrated a consistent upward trend in its reimbursement pipeline, increasing from 1,389 units in Q4 to 1,669 units, suggesting growing demand for its myoelectric orthosis products. The company's strategic focus on the large Medicare market is expected to redirect growth, with orthotics and prosthetics providers contributing approximately 22% of revenue in 2024. Furthermore, the recent positive ruling from the Centers for Medicare & Medicaid Services to include the MyoPro in Medicare Part B benefits significantly expands the potential market for Myomo, enhancing its growth prospects.

Bears say

Myomo Inc. has lowered its revenue guidance for 2025 to $40-42 million from a previous estimate of $50-53 million, indicating a significant decline in expected performance. Additionally, the company has reported a decrease in its backlog of insurance-authorized sales, which fell to 208 from 230 in the previous quarter, suggesting weakening demand for its products. Furthermore, the company's marketing strategies and pipeline quality have not met expectations, adversely affecting lead conversion rates and further contributing to a negative outlook for future revenue performance.

Myomo (MYO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myomo (MYO) Forecast

Analysts have given Myomo (MYO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Myomo (MYO) has a Strong Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myomo (MYO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.